Loading…
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-34M | $-33M | $-29M | -58.4% | - | - |
| 2024 | $0M | $-27M | $-24M | $-22M | -60.0% | - | - |
| 2023 | $0M | $-21M | $-19M | $-19M | -38.0% | - | - |
| 2022 | $0M | $-14M | $-14M | $-12M | -43.0% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 14 | 21.27 | 26.68 | 34.40 |
| Operating Income | -14 | -21.27 | -26.68 | -34.40 |
| EBITDA | -13.98 | -21.24 | -26.64 | -34.35 |
| EBIT | -14 | -21.27 | -26.68 | -34.40 |
| Pretax Income | -13.65 | -19.34 | -24.41 | -32.74 |
| Tax Provision | 0.03 | 0.04 | 0.03 | 0.03 |
| Net Income | -13.68 | -19.38 | -24.44 | -32.77 |
| Net Income Common Stockholders | -13.68 | -19.38 | -24.44 | -32.77 |
| Total Expenses | 14 | 21.27 | 26.68 | 34.40 |
| Research And Development | 7.84 | 13.11 | 19.06 | 24.61 |
| Selling General And Administration | 6.16 | 8.16 | 7.62 | 9.78 |
| Normalized EBITDA | -13.98 | -21.24 | -26.64 | -34.35 |
| Normalized Income | -13.68 | -19.38 | -24.44 | -32.77 |
| Basic EPS | -0.52 | -0.60 | -0.60 | -0.70 |
| Diluted EPS | -0.52 | -0.60 | -0.60 | -0.70 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0.21 | 0.21 | 0.21 | 0.21 |
| Net Income From Continuing Operation Net Minority Interest | -13.68 | -19.38 | -24.44 | -32.77 |
| Reconciled Depreciation | 0.03 | 0.03 | 0.04 | 0.04 |
| Net Income From Continuing And Discontinued Operation | -13.68 | -19.38 | -24.44 | -32.77 |
| Total Operating Income As Reported | -14 | -21.27 | -26.68 | -34.40 |
| Diluted Average Shares | 26.44 | 32.57 | 40.40 | 46.98 |
| Basic Average Shares | 26.44 | 32.57 | 40.40 | 46.98 |
| Diluted NI Availto Com Stockholders | -13.68 | -19.38 | -24.44 | -32.77 |
| Net Income Including Noncontrolling Interests | -13.68 | -19.38 | -24.44 | -32.77 |
| Net Income Continuous Operations | -13.68 | -19.38 | -24.44 | -32.77 |
| Other Income Expense | 0.35 | 1.93 | 2.27 | 1.66 |
| Other Non Operating Income Expenses | 0.35 | 1.93 | 2.27 | 1.66 |
| General And Administrative Expense | 6.16 | 8.16 | 7.62 | 9.78 |
| Other Gand A | 6.16 | 8.16 | 7.62 | 9.78 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| DiaMedica Therapeutics Inc.this co. | DMAC | $321M | - | 5.71 | -58.4% | -7.61 |
| Evolus, Inc. | EOLS | $337M | - | -14.59 | 223.5% | -14.56 |
| Monopar Therapeutics Inc. | MNPR | $335M | - | 2.43 | -10.0% | - |
| Cross Country Healthcare, Inc. | CCRN | $331M | - | 1.01 | -29.4% | 12.17 |
| SIGA Technologies, Inc. | SIGA | $325M |
| 14.16 |
| 1.63 |
| 11.7% |
| 7.02 |
| CapsoVision, Inc. | CV | $319M | - | 22.61 | -190.9% | -12.32 |
| ClearPoint Neuro, Inc. | CLPT | $310M | - | 10.84 | -91.1% | -14.85 |
| Anavex Life Sciences Corp. | AVXL | $302M | - | 2.39 | -48.9% | - |
| Compass Therapeutics, Inc. | CMPX | $301M | - | 1.51 | -33.8% | -1.40 |
| Peer Median | - | 14.16 | 2.01 | -31.6% | -6.86 | |